A bit disappointed. Sure there is a lot of good news and excitement, but we needed that paper published and were led to believe it was happening today. Also, the trial enrollment is dragging. Remember the 75 patient interim results do not fulfill the trial requirements, we're just optimistically hoping the FDA will bend, which they have never done for us. Giliead is flat out lapping us right now with a lesser product and it sucks.